


**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. Griffin Hospital</p> <p>2. 130 Division Street Derby, CT 06418</p>		<p>In accordance with letter dated February 01, 2022,</p>	<p>4. Expiration Date: October 31, 2023</p>
		<p>3. License No.: 06-13905-01 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-01300 Reference No.:</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 1 curie total</p>	<p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300 and in accordance with the letters dated August 23 and October 1, 2013, for iodine-131 administrations.</p>



**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 06-13905-01

Docket or Reference No.:  
030-01300

Amendment No. 43

**CONDITIONS**

10. Licensed material may be used or stored only at the licensee's facilities located at 130 Division Street, Derby, Connecticut.
11. The Radiation Safety Officer for this license is Christine Testo Cooper.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized User (M.D., D.O., etc.)</u> | <u>Material and Use</u>  |
|---|--|
| Bruce P. Arose, M.D.                      | 10 CFR 35.100, 10 CFR 35.200; Oral administration of sodium iodide iodine-131 in quantities less than or equal to 33 millicuries |
| Joseph G. Cardinale, M.D.                 | 10 CFR 35.300  |
| Joyce Chung, M.D.                         | 10 CFR 35.300  |
| Edward B. Cronin, M.D.                    | 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300  |
| Thomas H. Farquhar, M.D.                  | 10 CFR 35.100, 10 CFR 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies               |
| Brian J. Grogan, M.D.                     | 10 CFR 35.100, 10 CFR 35.200; Oral administration of sodium iodide iodine-131 in quantities less than or equal to 33 millicuries |
| Joanna E. Jacunski, M.D.                  | 10 CFR 35.100, 10 CFR 35.200; Oral administration of sodium iodide iodine-131 in quantities less than or equal to 33 millicuries |
| Prasanta K. Karak, M.D.                   | 10 CFR 35.100, 10 CFR 35.200   |
| Angabeen S. Khan, M.D.                    | 10 CFR 35.100, 10 CFR 35.200; Oral administration of sodium iodide iodine-131  |
| Jennifer C. Logan, M.D.                   | 10 CFR 35.100, 10 CFR 35.200   |
| Michael T. O'Loughlin, M.D.               | 10 CFR 35.100, 10 CFR 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies               |

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 06-13905-01

Docket or Reference No.:  
030-01300

Amendment No. 43

Authorized User (M.D., D.O., etc.)Material and Use

John Opalacz, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Jinnah A. Phillips, M.D.

10 CFR 35.100, 10 CFR 35.200

Ruben Rock, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Ronald J. Rosenberg, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Gabriela Z. Spilberg Missine, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300


Gregory T. Turner, M.D.

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Steven R. Urbanski, M.D.

10 CFR 35.100, 10 CFR 35.200; Oral administration of sodium iodide iodine-131 in quantities less than or equal to 33 millicuries

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit in 10 CFR 30.35(d) for which decommissioning financial assurance is required.



**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 06-13905-01

Docket or Reference No.:  
030-01300

Amendment No. 43

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.

- A. Application dated April 8, 2013 [ML13112A536]
- B. Letter dated August 23, 2013 [ML13249A321]
- C. Letter dated September 17, 2013 [ML13281A329]
- D. Letter dated October 1, 2013 [ML13281A330]
- E. Letter dated January 17, 2020 [ML20056E923]



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: June 13, 2022By: \_\_\_\_\_  
Robin Elliott  
Region 1